ZFSW
ZFSW
Cancer vaccine developer
ZFSW, founded in July, 1995 and headquartered in Chongqing, is an anti-cancer vaccine developer. The founder is Jiang Rensheng. Listed on the SZSE on September 28, 2010, the company's major shareholders are Jiang Rensheng, Jiang Lingfeng and Wu Guanjiang. Rivals that have direct and indirect competition with ZFSW include Kintor, HitGen, Aprea Therapeutics, BridgeBio Pharma, etc.
- All
- News
- Analysis
- Research
Briefing Jan 13, 2022 10:05 AM
· Healthcare
West Lake Omei won hundreds of millions of yuan of pre-A round of financing to help clinical diagnosis and AI new drug research and development based on proteome big data
Briefing Jan 12, 2022 09:28 AM
· Healthcare
Zhenge biology obtained US $100 million in round C financing, led by Goldman Sachs and Sofina
In depth
Briefing Jan 10, 2022 09:00 PM
· Healthcare
Bristol Myers Squibb entered the development of IPSC derived allogeneic cell therapy with more than US $3 billion
Briefing Jan 10, 2022 11:16 AM
· Healthcare
Lanjing microorganism completed a total of RMB 1.5 billion of Series B financing and accelerated the implementation of the "T-type" development strategy
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Real Estate, Industrials, FinancialsTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Research
Real Estate, Industrials, FinancialsLow-Carbon Industry Expansion - Key Studies From Chinese Companies
May 28, 2020 12:40 PM
Briefing Jan 06, 2022 05:02 PM
· Healthcare
Yourui pharmaceutical acquired Zhongjian pharmaceutical to create a special pharmaceutical company driven by two wheels of innovative pipeline R & D and commercialization of mature products
Briefing Jan 06, 2022 03:39 PM
· Healthcare
Xinmai medical announced strategic cooperation with rainbow medical, a famous medical device incubator in Israel
Briefing Jan 06, 2022 11:27 AM
· Healthcare
Hengrui medicine has been introduced for more than US $100 million! New antifungal drugs applied for listing in China
In depth
Healthcare
Dada group's revenue rose nearly 30% in the third quarter, and JD's "hour purchase" cont
Looking forward to the fourth quarter of 2021, dada Group expects its total revenue to be between 2 billion yuan and 2.1 billion yuan. On the premise that the last kilometer of dada express delivery service is consistent with the comparable basis, the total revenue in the fourth quarter of 2021 will achieve a year-on-year increase of 88% to 97%.
Nov 24, 2021 11:42 AM
Briefing Aug 03, 2021 11:10 AM
· Healthcare
Monitoring of main funds of star mine: Top 10 list of early trading
Insight
Briefing Jul 23, 2021 10:13 AM
· Healthcare
Pharmaceutical and biological stocks fell sharply in early trading
Briefing Jul 20, 2021 10:05 PM
US Senate committee to investigate the role of cryptocurrency in cyber crime
Briefing Jul 13, 2021 08:47 PM
· Healthcare
A breakthrough in cell therapy of solid tumor by Zhifei biological joint stock company
Briefing Jul 07, 2021 03:24 PM
· Healthcare
The first bank of China fund to release its second Quarterly Report
See more
Related Companies
EqualOcean Analysis
- Black Swans and Breakthroughs: China's Top 50 Innovative Public Firms in 2020
- China Speed: Two COVID-19 Vaccines Recognized by WHO
- After China's BNR and GTH Hit Nasdaq, Pan-Cancer Detector GRAIL Eyes IPO
- Bid for Molecular Tech in China's Early-Stage Cancer Detection Market
- More Room for the Medical Device Market to Grow in China
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.